United Kingdom, Aug. 28 -- United Kingdom based Revvity (UK) Limited has secured contract from NHS England for Commercial Kit for screening for hereditary tyrosinemia type 1 (HT1). The value of the contract is worth 1677290 GBP.
Published by HT Digital Content Services with permission from Pivotal Sources....